Editorial principle
Trials that failed, returned null results, were withdrawn, or were never funded are listed here alongside successful ones and labelled as such. Publication bias is one of the main reasons longevity claims outrun their evidence; reporting negative results transparently is a requirement of this database, not an omission.
14 trials · 1 negative, withdrawn or never launched
- Academic sponsor · American Federation for Aging ResearchRecruiting
Targeting Aging with Metformin (TAME)
- Phase
- Phase III
- Category
- Metabolic
- Enrollment
- 3,000 target
- Timeline
- 2024 – ongoing
Intervention
Metformin 1500mg/day
Reported summary
Landmark trial testing metformin's ability to delay age-related diseases in non-diabetic adults aged 65-79.
- Industry sponsor · UNITY BiotechnologyActive
UNITY Biotechnology UBX1325 Senolytic Trial
- Phase
- Phase II
- Category
- Senolytics
- Enrollment
- 160 target
- Timeline
- 2022 – ongoing
Intervention
UBX1325 (Bcl-xL inhibitor)
Reported summary
Evaluating a senolytic therapy targeting Bcl-xL in patients with diabetic macular edema as an aging-related disease model.
- Academic sponsor · AgelessRx / University of TexasActive
Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL)
- Phase
- Phase II
- Category
- mTOR Inhibition
- Enrollment
- 200 target
- Timeline
- 2021 – ongoing
Intervention
Rapamycin 5-10mg weekly
Reported summary
Decentralized trial studying rapamycin's effects on aging biomarkers and healthspan in healthy adults.
- Industry sponsor · Intervene ImmuneActive
TRIIM-X (Thymus Regeneration)
- Phase
- Phase II
- Category
- Immune Rejuvenation
- Enrollment
- 85 target
- Timeline
- 2020 – ongoing
Intervention
Growth hormone + DHEA + metformin
Reported summary
Follow-up to TRIIM trial that demonstrated thymus regeneration and epigenetic age reversal.
No registry record - Triple Helix sponsor · Altos LabsActive
Altos Labs — Cellular Reprogramming Program
- Phase
- Preclinical/Phase I
- Category
- Epigenetic Reprogramming
- Enrollment
- No human enrollment listed
- Timeline
- 2022 – ongoing
Intervention
Partial Yamanaka factor reprogramming
Reported summary
Backed by $3B in funding, Altos Labs is advancing partial cellular reprogramming using Yamanaka factors to reverse aging at the cellular level. Partnership with Stanford, UC Berkeley, and Cambridge.
No registry record - Triple Helix sponsor · Retro BiosciencesActive
Retro Biosciences — Longevity Platform
- Phase
- Preclinical
- Category
- Multi-Modal
- Enrollment
- No human enrollment listed
- Timeline
- 2023 – ongoing
Intervention
Autophagy activation, plasma-inspired therapeutics, partial reprogramming
Reported summary
Sam Altman-backed $180M venture pursuing three parallel longevity approaches. University-industry collaboration with UCSF and Stanford.
No registry record - Triple Helix sponsor · Calico Labs (Alphabet)Active
Calico Labs — Aging Interventions Portfolio
- Phase
- Phase I/II
- Category
- Multi-Modal
- Enrollment
- No human enrollment listed
- Timeline
- 2013 – ongoing
Intervention
Multiple undisclosed small molecules and biologics
Reported summary
Alphabet's longevity company with $2.5B in funding. Partners with AbbVie on aging drug development. Partnership with Broad Institute and MIT.
No registry record - Triple Helix sponsor · Biosplice TherapeuticsActive
Biosplice — Wnt Pathway Modulation
- Phase
- Phase III
- Category
- Tissue Regeneration
- Enrollment
- 1,200 target
- Timeline
- 2019 – ongoing
Intervention
Lorecivivint (CLK/DYRK1A inhibitor)
Reported summary
Disease-modifying therapy for osteoarthritis via Wnt pathway modulation. University-industry model with Scripps Research collaboration.
- Triple Helix sponsor · Turn BiotechnologiesActive
Turn Biotechnologies — ERA Platform
- Phase
- Preclinical
- Category
- Epigenetic Reprogramming
- Enrollment
- No human enrollment listed
- Timeline
- 2020 – ongoing
Intervention
Epigenetic Reprogramming of Aging (ERA) mRNA cocktails
Reported summary
Developing mRNA-based epigenetic reprogramming targeting specific tissues. Stanford-derived technology with government grants from NIA.
No registry record - Triple Helix sponsor · Rejuvenate BioActive
Rejuvenate Bio — Gene Therapy for Aging
- Phase
- Preclinical/Phase I
- Category
- Gene Therapy
- Enrollment
- No human enrollment listed
- Timeline
- 2022 – ongoing
Intervention
Combination gene therapy (OSK factors + telomerase + follistatin)
Reported summary
Harvard-spun-out company developing multi-gene therapy for aging reversal. Demonstrated lifespan extension in aged mice. NIH SBIR grants support translational work.
No registry record - Triple Helix sponsor · Loyal for DogsActive
Loyal — Large Dog Longevity Trial (LOY-002)
- Phase
- Phase II/III
- Category
- Metabolic
- Enrollment
- 1,000 target
- Timeline
- 2023 – ongoing
Intervention
LOY-002 (mTOR/IGF-1 modulation)
Reported summary
FDA conditional approval pathway for first anti-aging drug. Testing in large breed dogs as translational model. University of Washington partnership.
No registry record - Triple Helix sponsor · Cambrian BioActive
Cambrian Bio — Aging Drug Pipeline
- Phase
- Phase I
- Category
- Multi-Modal
- Enrollment
- No human enrollment listed
- Timeline
- 2021 – ongoing
Intervention
Multiple programs: senolytics, immune aging, metabolic modulators
Reported summary
Portfolio approach to aging with 15+ spinout companies. Deep ties to Harvard, MIT, and Mayo Clinic. Government-supported through ARPA-H initiatives.
No registry record - Industry sponsor · Novartis / resTORbioCompleted — null / negative
Rapamycin for Immune Senescence and Aging
- Phase
- Phase I/II
- Category
- mTOR Inhibition
- Enrollment
- 652 target
- Timeline
- 2018 – 2020
Intervention
RTB101 (mTORC1 inhibitor)
Negative / null result
Tested mTOR inhibition for improving immune function in elderly. Phase 3 PROTECTOR trials did not meet endpoints.
No registry record - Government sponsor · NIA / NIHCompleted
CALERIE Phase 2 (Caloric Restriction)
- Phase
- Phase II
- Category
- Caloric Restriction
- Enrollment
- 220 target
- Timeline
- 2007 – 2015
Intervention
25% caloric restriction for 2 years
Reported summary
Definitive human caloric restriction trial showing biological age reduction and improved cardiometabolic markers.
Recently updated — awaiting review
checkingA weekly routine queries the public registry for every tracked intervention and flags studies that are newly registered or newly completed. These are candidates for editorial review only — nothing here is curated or endorsed until it appears in the list above.